<DOC>
	<DOCNO>NCT00648908</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability activity Fampridine-SR administer 36 additional month , become commercially available whichever come first , subject previously participate Acorda Therapeutics Protocol MS-F203 .</brief_summary>
	<brief_title>Open-Label Extension Study Evaluate Safety , Tolerability Activity Oral Fampridine-SR Tablets Multiple Sclerosis Patients Who Participated MS-F203 Trial</brief_title>
	<detailed_description>Multiple Sclerosis ( MS ) disorder body 's immune system affect central nervous system ( CNS ) . Normally , nerve fiber carry electrical impulse spinal cord , provide communication brain arm legs . In people MS , fatty sheath surround insulate nerve fiber ( call `` myelin '' ) deteriorate , cause nerve impulse slow stopped . As result , patient MS may experience period muscle weakness symptom numbness , loss vision , loss coordination , paralysis , spasticity , mental physical fatigue decrease ability think and/or remember . These period illness may come ( exacerbation ) go ( remission ) . Fampridine-SR experimental drug report possibly improve muscle strength walk ability people MS . This study evaluate effect possible risk take Fampridine-SR MS patient long period time .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>subject must previously enrol Acorda Therapeutics MSF203 study multiple sclerosis receive either FampridineSR placebo subject man woman clinical definite multiple sclerosis define McDonald ( McDonald WI , et al . Recommended Diagnostic Criteria Multiple Sclerosis ; Guidelines International Panel Diagnosis Multiple Sclerosis ; Annals Neurology . 2001 ; 50 : 121127 ) subject must least 18 year age . Any subject age 70 must good overall health judgment Investigator subject must adequate cognitive function , judge Investigator , understand sign IRB/REBapproved inform consent form prior performance studyspecific procedure willing comply require scheduling assessment protocol subject woman childbearing potential , regardless sexual activity , must negative urine pregnancy test Screening Visit . woman either pregnant breastfeeding , woman childbearing potential ( define surgically sterile least two year post menopausal ) engage active heterosexual relation , use one follow birth control method : tubal ligation , implantable contraception device , oral , patch , injectable transdermal contraceptive , barrier method sexual activity restrict vasectomized partner . subject discontinue prematurely MSF203 study subject history seizure evidence past , possible , epileptiform activity EEG subject either clinically significant abnormal ECG laboratory value ( ) Screening visit , judge Investigator would preclude entry study . ECG laboratory result Visit 6 repeat result Visit 7 MSF203 study may use baseline current study subject angina , uncontrolled hypertension , clinically significant cardiac arrhythmia , clinically significant cardiovascular abnormality , judge Investigator subject know allergy pyridinecontaining substance inactive ingredient FampridineSR tablet ( hydroxypropyl methylcellulose , microcrystalline cellulose , colloidal silicon dioxide , magnesium stearate , opadry white ( tablet film coat ) ) subject receive investigational drug , except FampridineSR match placebo protocol MSF203 , within 30 day Screening Visit . Subject schedule enroll investigational drug trial time study . subject history drug alcohol abuse within past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>walk</keyword>
	<keyword>leg strength</keyword>
	<keyword>demyelination</keyword>
</DOC>